Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MED-PSO biomarker study of deucravacitinib in classic and hard-to-treat plaque psoriasis
2023-508948-22-00Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deucravacitinib in plaque psoriasis, psoriasis and inverse psoriasis, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in inflammatory gene expression after 16 weeks. Started Jan 2025; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasispsoriasisinverse psoriasis
Beyond the preview
Go deeper on 2023-508948-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508948-22-00.